International investment and executive reorganisation are transforming India’s healthcare industry, with KKR’s potential billion-dollar stake in Medicover and key leadership appointments signalling a new phase of growth and innovation.
India’s healthcare sector is drawing fresh capital and new leadership as global investors and drugmakers move to expand their footprint in a market that continues to grow in scale and sophistication. According to The Economic Times, KKR is in advanced talks to buy a significant stake in Medicover’s Indian hospital business in a deal worth more than $1 billion, a transaction that would add to the private equity firm’s already expanding exposure to the country’s healthcare market. Medicover operates 26 hospitals with about 6,000 beds in India, putting it in competition with Apollo Hospitals, Aster Hospitals and Fortis Healthcare.
The proposed Medicover deal would follow KKR’s earlier move into the sector. Business Wire reported in February that the firm had agreed to acquire a controlling stake in Healthcare Global Enterprises for $400 million, becoming the largest shareholder in the oncology-focused provider. That transaction underlined how international investors are treating Indian healthcare as a long-term growth story, with hospitals seen as attractive assets because of rising demand, greater insurance penetration and continued investment needs.
Leadership changes are also reshaping the industry’s next phase. Sanofi has named Archana Subramanya as head of its India research and development hub in Hyderabad, where she will be responsible for linking local work more closely with the company’s global research network. At Indira IVF Group, Devendrasingh Rajput has been promoted to chief growth officer, expanding his remit to include business-to-business and pathology lab operations, as well as consumer marketing and projects.
In pharmaceuticals and biologics, Rajpal Rana has joined Alkem as senior vice president for the acute cluster, while Shilpa Biologicals has appointed Dr. Uday Harle as chief executive, effective August 3, 2026. The company says Harle’s background in clinical development, vaccines and regulatory strategy will support its push into biologics and advanced therapies, including antibody-drug conjugates. Taken together, these moves suggest an industry in which capital and specialist leadership are increasingly being deployed side by side to drive the next wave of expansion.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
